Searching for aurora in the night of sarcoma phase II trials: isn't it time to move to second gear?

about

Searching for aurora in the night of sarcoma phase II trials: isn't it time to move to second gear?

Item

http://www.wikidata.org/entity/Q53041284

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Searching for aurora in the ni ...... t time to move to second gear?

@en

Searching for aurora in the ni ...... t time to move to second gear?

@nl

type

Item

label

Searching for aurora in the ni ...... t time to move to second gear?

@en

Searching for aurora in the ni ...... t time to move to second gear?

@nl

prefLabel

Searching for aurora in the ni ...... t time to move to second gear?

@en

Searching for aurora in the ni ...... t time to move to second gear?

@nl

P1476

Searching for aurora in the ni ...... t time to move to second gear?

@en

P2093

M Toulmonde

http://www.w3.org/2001/XMLSchema#string

P2860

Drugging MYCN through an allosteric transition in Aurora kinase A

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7

KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors

Key roles for MYC, KIT and RET signaling in secondary angiosarcomas

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema

The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy

P304

1815-1817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1093/ANNONC/MDW318

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27502727

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial